Track Record of Identifying Rare Wealth CreatorsTrack Record of Identifying Rare Wealth Creators

Behavioral Finance

May 5, 2026
Dark blue page with a title 'Other Income as a Percentage of' and subtitle 'The 30-Second Forensic Earnings-Quality Filter'; a horizontal bar chart shows yearly values: FY20 3.2%, FY21 2.8%, FY22 2.1%, FY23 1.6%, FY24 1.3%, FY25 1.1% (green bar).

Other Income as a Percentage of PBT: The 30-Second Forensic Earnings-Quality Filter

A long-form educational deep-dive on Other Income as a percentage of Profit Before Tax — the 30-second forensic earnings-quality filter that separates real Indian operating businesses from non-operating bookkeepers. Illustrated using Titan Biotech FY25 audited disclosures (operating-led ~₹214 Cr revenue, ~18-22% EBITDA margin, CFO/Operating Profit at ~103%, total borrowings ₹3 Cr) as a positive educational example. Educational content only — not a buy/sell recommendation.
May 5, 2026
Dark blue page with title 'Economic Goodwill' and green subtitle; below is a two-by-two color block diagram: top-left 'Trader' (gray), top-right 'COMPOUNDER' (green), bottom-left 'Drift' (light gray), bottom-right 'Speculator' (orange).

Economic Goodwill: Warren Buffett’s 1983 Berkshire Letter Appendix on the Real Source of Compounding

Buffett's 1983 appendix split goodwill into two: the accountant's residual on the balance sheet, and the inflation-resistant economic goodwill that compounds wealth. Titan Biotech FY25's high returns on a modest tangible base read like the second.
May 4, 2026
Header with the title 'The Gambler’s Fallacy and Hot-Hand Fallacy' and a four-panel color infographic showing Lucky, Confused, DISCIPLINED INVESTOR, and BIAS-TRAPPED beneath it.

The Gambler’s Fallacy and Hot-Hand Fallacy: Tversky, Kahneman & Gilovich on the Misperception of Random Sequences

Tversky-Kahneman 1971 and Gilovich-Vallone-Tversky 1985 established that humans systematically misread short random sequences. Indian NSE/SEBI behavioural data show retail investors compound the error. A counter-measure checklist plus an illustrative Titan Biotech FY25 case study of process-over-pattern corporate behaviour.
May 4, 2026
Infographic bar chart titled PEG Ratio: Growth-Adjusted Valuation by year, showing FY20 38 down to FY25 16, with FY25 bar highlighted in green.

PEG Ratio: Peter Lynch’s Growth-Adjusted Valuation Framework

Peter Lynch's Price-to-Earnings-to-Growth ratio reframes valuation: a high P/E may be cheap if growth is high, a low P/E may be a trap if growth is fading. Using Titan Biotech FY25 audited inputs (10-yr revenue CAGR ~15%, 10-yr PAT CAGR ~29%, CFO/Operating Profit ~103%) as a clean educational illustration.
info@multibaggershares.com